CA2441335A1 - Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer - Google Patents
Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer Download PDFInfo
- Publication number
- CA2441335A1 CA2441335A1 CA002441335A CA2441335A CA2441335A1 CA 2441335 A1 CA2441335 A1 CA 2441335A1 CA 002441335 A CA002441335 A CA 002441335A CA 2441335 A CA2441335 A CA 2441335A CA 2441335 A1 CA2441335 A1 CA 2441335A1
- Authority
- CA
- Canada
- Prior art keywords
- rar
- formula
- cytotoxic agent
- selected cytotoxic
- paclitaxel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27775401P | 2001-03-22 | 2001-03-22 | |
| US60/277,754 | 2001-03-22 | ||
| PCT/US2002/008718 WO2002078620A2 (en) | 2001-03-22 | 2002-03-22 | Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2441335A1 true CA2441335A1 (en) | 2002-10-10 |
Family
ID=23062213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002441335A Abandoned CA2441335A1 (en) | 2001-03-22 | 2002-03-22 | Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1383491A2 (https=) |
| JP (1) | JP2004528316A (https=) |
| KR (1) | KR20030086314A (https=) |
| CN (1) | CN1498105A (https=) |
| BR (1) | BR0207681A (https=) |
| CA (1) | CA2441335A1 (https=) |
| CZ (1) | CZ20032540A3 (https=) |
| DE (1) | DE02733871T1 (https=) |
| ES (1) | ES2214985T1 (https=) |
| HU (1) | HUP0400255A2 (https=) |
| IL (1) | IL157358A0 (https=) |
| MX (1) | MXPA03008403A (https=) |
| PL (1) | PL368946A1 (https=) |
| TR (1) | TR200400812T3 (https=) |
| WO (1) | WO2002078620A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5113038B2 (ja) * | 2006-03-23 | 2013-01-09 | テムリック株式会社 | 癌治療用キットおよび癌治療用医薬組成物 |
-
2002
- 2002-03-22 WO PCT/US2002/008718 patent/WO2002078620A2/en not_active Ceased
- 2002-03-22 TR TR2004/00812T patent/TR200400812T3/xx unknown
- 2002-03-22 CA CA002441335A patent/CA2441335A1/en not_active Abandoned
- 2002-03-22 IL IL15735802A patent/IL157358A0/xx unknown
- 2002-03-22 DE DE0001383491T patent/DE02733871T1/de active Pending
- 2002-03-22 JP JP2002576888A patent/JP2004528316A/ja not_active Withdrawn
- 2002-03-22 PL PL02368946A patent/PL368946A1/xx not_active Application Discontinuation
- 2002-03-22 HU HU0400255A patent/HUP0400255A2/hu unknown
- 2002-03-22 ES ES02733871T patent/ES2214985T1/es active Pending
- 2002-03-22 BR BR0207681-0A patent/BR0207681A/pt not_active Application Discontinuation
- 2002-03-22 MX MXPA03008403A patent/MXPA03008403A/es unknown
- 2002-03-22 CN CNA028070011A patent/CN1498105A/zh active Pending
- 2002-03-22 KR KR10-2003-7012217A patent/KR20030086314A/ko not_active Withdrawn
- 2002-03-22 EP EP02733871A patent/EP1383491A2/en not_active Withdrawn
- 2002-03-22 CZ CZ20032540A patent/CZ20032540A3/cs unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1498105A (zh) | 2004-05-19 |
| PL368946A1 (pl) | 2005-04-04 |
| IL157358A0 (en) | 2004-02-19 |
| BR0207681A (pt) | 2004-07-27 |
| HUP0400255A2 (hu) | 2004-08-30 |
| KR20030086314A (ko) | 2003-11-07 |
| DE02733871T1 (de) | 2004-08-26 |
| TR200400812T3 (tr) | 2004-07-21 |
| ES2214985T1 (es) | 2004-10-01 |
| JP2004528316A (ja) | 2004-09-16 |
| WO2002078620A2 (en) | 2002-10-10 |
| CZ20032540A3 (cs) | 2004-05-12 |
| WO2002078620A3 (en) | 2003-04-17 |
| MXPA03008403A (es) | 2004-01-29 |
| EP1383491A2 (en) | 2004-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Buchwald et al. | HDACi–targets beyond chromatin | |
| Leeman et al. | STAT3 as a therapeutic target in head and neck cancer | |
| Alvarez et al. | Structure, function and modulation of retinoic acid receptor beta, a tumor suppressor | |
| US6130230A (en) | Therapeutic combinations of RAR antagonists and RXR agonists and use thereof | |
| ES2544482T3 (es) | Compuesto rexinoide que tiene un grupo alcoxi | |
| Zusi et al. | Selective retinoids and rexinoids in cancer therapy and chemoprevention | |
| Campbell et al. | Expression of retinoic acid receptor-β sensitizes prostate cancer cells to growth inhibition mediated by combinations of retinoids and a 19-nor hexafluoride vitamin D3 analog | |
| WO2008144475A1 (en) | Methods and compositions for treating cancer | |
| US20090203661A1 (en) | Betulinic acid, derivatives and analogs thereof and uses therefor | |
| Nikitakis et al. | Targeting the STAT pathway in head and neck cancer: recent advances and future prospects | |
| JP2014076953A (ja) | レチノイドｘ受容体パーシャルアゴニスト化合物及びこのレチノイドｘ受容体パーシャルアゴニスト化合物を有効成分として含有する薬剤 | |
| Lo et al. | Effects of all-trans retinoic acid, retinol, and β-carotene on murine macrophage activity | |
| AU701790B2 (en) | Method for treating cancers using 6-{3-{1-adamantyl}- 4-hydroxyphenyl} | |
| Nagpal et al. | Retinoids as anti-cancer agents | |
| AU2011249857B2 (en) | Methods and compositions related to a retinoid receptor-selective pathway | |
| Vitoux et al. | Acute promyelocytic leukemia: new issues on pathogenesis and treatment response | |
| AU773928B2 (en) | Compositions and methods for treatment of hyperproliferative diseases | |
| US20040122080A1 (en) | Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer | |
| Marzo-Mas et al. | Effects on tubulin polymerization and down-regulation of c-Myc, hTERT and VEGF genes by colchicine haloacetyl and haloaroyl derivatives | |
| Wozniak et al. | Parthenolide complements the cell death-inducing activity of doxorubicin in melanoma cells | |
| CA2441335A1 (en) | Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer | |
| AU2002305072A1 (en) | Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer | |
| JP2013177329A (ja) | Ｒｘｒパーシャルアゴニスト | |
| Xie et al. | 5-allyl-7-gen-difluoromethoxychrysin enhances TRAIL-induced apoptosis in human lung carcinoma A549 cells | |
| US6211239B1 (en) | Method for treating or preventing breast cancer or leukemia using 6-[3-[1-adamantyl]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |